Showing results (51-60 of 72) with videos related to
Sort By:
Pageof 8
The Journal of Antimicrobial Chemotherapy|May 16, 2020
Letermovir breakthroughs during the French Named Patient Programme: interest of monitoring blood concentration in clinical practiceS Alain, L Feghoul, S Girault, et al.The Journal of Antimicrobial Chemotherapy|December 5, 2019
Long-term follow-up of HIV-infected patients on dolutegravir monotherapyG Tebano, C Soulié, L Schneider, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 26, 2010
Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)C Delaugerre, J F Buyck, G Peytavin, et al.Infection|October 25, 2013
Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity scoreF Caby, L Schneider, C Blanc, et al.Journal of Clinical Microbiology|July 6, 2000
Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistanceM Mouroux, A Yvon-Groussin, G Peytavin, et al.JAMA|January 14, 2000
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team)D Descamps, P Flandre, V Calvez, et al.The Journal of Antimicrobial Chemotherapy|July 31, 2018
Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West AfricaD B Fofana, M d'Almeida, S Lambert-Niclot, et al.The Journal of Antimicrobial Chemotherapy|December 8, 2017
Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemiaS Seang, L Schneider, T Nguyen, et al.The Journal of Antimicrobial Chemotherapy|June 12, 2016
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemiaC Katlama, C Soulié, F Caby, et al.The Journal of Antimicrobial Chemotherapy|May 29, 2016
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patientsL Bocket, G Peytavin, E K Alidjinou, et al.Pageof 8